Personalised melanoma vaccines prolong survival in largest trial yet...


New Scientist | 2022-12-15 11:33 UTC

People who received a personalised melanoma skin cancer vaccine on top of a standard treatment were 44 per cent less likely to die over the study period than those who had the standard treatment alone

By Anonymous Submission on 2022-12-30 03:45 UTC
  • Need an account?  
    or